Genmab — Juni 2015
-
More recently, targeted treatment with oral tyrosine kinase inhibitors has
resulted in dramatic effects; however, these agents are not curative, only
achieve low complete response (CR) rates, have limited long-term safety
data, and resistance has been reported.3,4 They are therefore unlikely to
entirely replace anti-CD20 mAb-based therapy -
-
Ja grækerne spøger igen
-
Enig. Det eneste markedet ikke kan lide er usikkerhed. Nærmest ligegyldig hvilken løsning er vil det give lettelse
-
600 gik ud der
-
det er egentlig utroligt at de bliver ved med at shorte i den .. der må sku´være en dagsorden når man shorter det ser ud til at de åbenbart er lige om kursen falder eller stiger så tjener man penge alligevel.. måske er der noget skattetænkning indregnet ved at man kan trække tab fra og derved mindske overskud .. ja jeg ved det simpelt hen ikke.. men et eller andet "rotten" er der altså -:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind